Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, which, without treatment, can cause significant renal dysfunction. We evaluated the effects of enzyme replacement therapy with agalsidase alfa on renal decline in patients with Fabry disease using data from the F...
Main Authors: | Markus Cybulla, Kathleen Nicholls, Sandro Feriozzi, Aleš Linhart, Joan Torras, Bojan Vujkovac, Jaco Botha, Christina Anagnostopoulou, Michael L. West |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/16/4810 |
Similar Items
-
Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
by: Feriozzi S, et al.
Published: (2024-04-01) -
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
by: Aleš Linhart, et al.
Published: (2023-10-01) -
Biomarkers of Fabry Nephropathy: Review and Future Perspective
by: Tina Levstek, et al.
Published: (2020-09-01) -
Clinical and Histopathological Factors Influencing IgA Nephropathy Outcome
by: Andrzej Konieczny, et al.
Published: (2021-09-01) -
Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
by: Hakan Ozer, et al.
Published: (2024-03-01)